A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013 [EXTENSION OF 700009915]

Trial Profile

A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013 [EXTENSION OF 700009915]

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; AS04A
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms HPV-025 EXT 013
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00877877).
    • 21 Feb 2013 Planned number of patients changed to 600.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top